Soft‐tissue sarcomas (STS) are rare tumors that account for 1% of all adult malignancies,
with over 100 different histologic subtypes occurring predominately in the trunk, extremity …

We describe here the main natural compounds used in cancer therapy and prevention, the
historical aspects of their application and pharmacognosy. Two major applications of these …

Purpose This multicenter study, to our knowledge, is the first phase III trial to compare
trabectedin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma …

Background Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in
patients with advanced non-adipocytic soft-tissue sarcoma. We investigated the effect of …

Soft tissue sarcomas (STS) are rare solid tumors of mesenchymal cell origin that display a
heterogenous mix of clinical and pathologic characteristics. STS can develop from fat …

Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a
heterogenous mix of clinical and pathologic characteristics. STS can develop from fat …

Purpose To evaluate the safety and efficacy of trabectedin in a phase II, open-label,
multicenter, randomized study in adult patients with unresectable/metastatic liposarcoma or …

Background Previous studies have suggested that trabectedin (ecteinascidin-743) could
have antitumour activity in soft-tissue sarcoma. We aimed to study the usefulness of …

Soft-tissue sarcoma (STS) is a rare and heterogeneous group of tumours that comprise
approximately 1% of all adult cancers, and encompass over 50 different subtypes. These …

Sarcomas comprise a heterogeneous group of mesenchymal neoplasms. They can be
grouped into 2 general categories, soft tissue sarcoma and primary bone sarcoma, which …